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es any additive toxicity from F16, consis-
tent with a requirement for mitochondrial
accumulation of the compound. Dose-
response measurements at low concen-
trations of F16 (100 nM) should demon-
strate concordance between the direct
mitochondrial effects of F16 (uncoupling,
increased O2 consumption) and cell toxic-
ity. Structure-activity relationships may
demonstrate that cytotoxicity of a series of
related compounds is correlated with rela-
tive mitochondrial uptake. Despite strong
correlative evidence, nonmitochondrial
sites of action can emerge to complicate
conclusions about mechanism. MKT-077,
a rhodacyanine DLC dye entered into
Phase I clinical trials, has since been
reported to have direct effects on addi-
tional targets, including telomerase inhibi-
tion, crosslinking of F actin, and reactiva-
tion of wild-type p53 via binding the
hsp70 family member, mot-2 (mortalin)
(Maruta et al., 1999; Naasani et al.,
1999; Wadhwa et al., 2000).
The central importance of mito-
chondria in apoptotic cell death path-
ways offers up several molecular tar-
gets in mitochondria that are highly
expressed in cancer cells. Foremost
among these are the Bcl-2-related sur-
vival proteins, Bcl-2 and Bcl-xL. There
are now several examples of small mol-
ecules that bind to the hydrophobic
groove of these proteins and either dis-
place proapoptotic family members
(Bax, Bak) from a heterodimeric com-
plex or alter membrane topology of the
survival proteins (Degterev et al., 2001;
Tzung et al., 2001). Although the report
by Fantin et al. (2002) does not examine
the effect of Bcl-2 expression on F16
cytotoxicity, a separate group compared
the ability of Bcl-2 to rescue L929 cells
treated with neutral hydrophilic, anionic
lipophilic, and cationic lipophilic photo-
sensitizers (Klein et al., 2001). Over-
expression of Bcl-2 sensitized L929
cells to the cationic drug, Victoria Blue
BO, even in the dark, associated with
increased mitochondrial uptake. Since
the proposed functions of the Bcl-2 anti-
apoptotic proteins include regulation of
mitochondrial membrane permeability,
compounds with selective accumulation
in mitochondria, including F16, may
represent another approach to eradi-
cate cancer cells expressing high levels
of Bcl-2/Bcl-xL and resistant to standard
chemotherapy.
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Functions of p53 suppress critical consequences of damage 
and repair in the initiation of cancer
A pivotal study reveals a long-sought-after mechanism for gene amplification and provides important implications for
oncogenesis.
One of the most frequent and mystifying
types of abnormalities observed in
human carcinomas is the amplification
of large genomic regions associated
with complex chromosomal rearrange-
ments (complicons). These abnormali-
ties are believed to be the functional
basis for tumor progression and drug
resistance both in vivo and in vitro
(Kuehl and Bergsagel, 2002; Federspiel
et al., 1984). In a recent publication by
Zhu et al., the molecular dissection of
these complicated structures in the
experimental generation of lymphomas
has illuminated a molecular mechanism
of gene amplification and several factors
that can modulate this process. As the
result of a long series of fundamental
observations, culminating in a recent
elegant study (Zhu et al., 2002), the Alt
laboratory has identified several of the
major determinants that generate the
intermediates in this process and has
been able to propose a mechanism.
They show that, in a setting where V(D)J
recombination is initiated, deficiencies in
both p53 function and nonhomologous
end-joining abilities conspire to gener-
ate complex genomic rearrangements.
In this system, the chromosomal
rearrangement is initiated by RAG
(recombination-activating genes)-medi-
ated recombination that catalyzes a
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DNA double-strand break. The inability
to repair this break (NHEJ dysfunction)
and the inability to eliminate the dam-
age-containing cell (p53 dysfunction)
allows the cleaved chromosomes to
associate into dicentric intermediates
that, through subsequent bridge-fusion-
breakage events in the surviving cell,
generates the amplified and rearranged
units. The chromosomal intermediates
in this process have been documented
using contemporary cytogenetic ad-
vances and provide support for the pre-
dicted mechanism. Although V(D)J
recombination is a specialized process
and the only site-directed recombination
process known in vertebrates, it holds
lessons for a much broader appreciation
of the factors that influence cancer initia-
tion.
The astounding generation of multi-
ple copies of genomic DNA (i.e., gene
amplification) in tumor cells was first
described in the 1970s. Early chromo-
some analysis by Biedler identified
unique and unusual chromosomal
abnormalities (double-minute chromo-
somes and homogeneously staining
regions) that were associated with drug
resistance in human tumor cells (Biedler
and Spengler, 1976). Rigorous, ground-
breaking studies by Alt and coworkers in
the Schimke laboratory identified the
molecular basis of drug resistance and
the accompanying chromosomal abnor-
malities as amplification of genomic
sequences (Alt et al., 1978). Over the
last 25 years, many laboratory groups
have sought understanding of this
process for several reasons. The first
and most direct reason is because the
process of gene amplification can cir-
cumvent drug efficacy during chemo-
therapy. A molecular understanding of
the process should allow us to prevent
or reduce the generation of drug resis-
tance. This is true for standard chemo-
therapies that have been used for
decades, as well as the new “targeted”
drugs that have been designed to abro-
gate the function of specific mutated
enzymes. STI-571 is a prime example of
this, since amplification of the re-
arranged BCR-ABL locus contributes to
drug resistance and their eventual thera-
peutic failure (Gorre et al., 2001).
However, while elucidation of the
generation of amplified loci and compli-
cons is important in its own right, it also
holds critical significance in the greater
context of tumorigenesis. Thus, a sec-
ond and equally important reason to
study these processes is to gain under-
standing of how a normal, nontrans-
formed cell loses genomic integrity. It
has long been appreciated that normal
somatic mammalian cells rarely, if ever,
amplify genomic sequences (Tlsty,
1990; Wright et al., 1990), yet this event
occurs readily in transformed cells. The
acquisition of drug resistance (via gene
amplification) and tumorigenic progres-
sion in transformed cells share several
critical traits that suggest that under-
standing the former will contribute to
controlling the latter. Both drug resis-
tance and tumorigenesis are multistep
processes whose products are believed
to emerge from step-wise selection,
both depend on functional conse-
quences of identical chromosomal
abnormalities, and both demonstrate
dynamic instability and heterogeneity in
their phenotype. Finally, both drug resis-
tance and tumorigenesis are modulated
by the same agents, and both can be
enhanced by viruses and exposure to
carcinogenic agents. The postulated
mechanism of complicon formation in
Zhu et al. provides the potential to inte-
grate these diverse observations into a
unified vision.
The initiating event in complicon for-
mation is a DNA double-strand break.
As indicated in Figure 1, there are many
processes that occur within the cell as a
consequence of normal metabolism that
can generate this initiating event.
Additionally, there is a plethora of
exogenous agents (insults and stresses)
that also generate DNA lesions and sub-
sequent DNA breaks. Hence, in addition
to carcinogen exposure, physiological
processes as diverse as inflammation,
Figure 1. Generation of complicons
In a properly functioning cell (A), the majority of continually produced DNA damage is
repaired. The few lesions that avoid repair activate functions of p53 that cause these cells to be
cleared from the population. Inadequate removal of damaged DNA can overwhelm the sec-
ond line of defense (p53), and rare cells with rearrangements survive (B). Finally, in cells that
have lost both NHEJ and p53 functions (C), abnormal cells are readily produced and are no
longer cleared from the population. These cells continue to proliferate and acquire the
genomic changes that allow for malignant outgrowth.
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aging, and hypoxia can all potentially
generate a multitude of initiating events.
Each cell deals with the consequences
of these processes every day.
The first line of defense against
these assaults is the prevention or
removal of the DNA double-strand
breaks. As demonstrated by the Zhu
study, the RAG-induced breaks invoke
the action of a series of repair enzymes
(Ku70, Ku80, DNA-PKC) that have a
dual function in site-directed recombina-
tion and repair of double-strand breaks.
These same proteins have more recent-
ly been reported to play a critical role in
the capping of mammalian telomeric
structures (Bailey et al., 1999; Goytisolo
et al., 2001). Thus, critically short or
uncapped telomeres rely on the same
reparative proteins as the radiation-
induced breaks and the free radical-
induced scissions. Deficiencies in these
protein functions probably contribute to
the generation of complicon intermedi-
ates by failure to repair recombinogenic
chromosome ends. When these pro-
teins are inactivated, chromosomal re-
arrangements are generated, but in the
presence of functional p53, these cells
are cleared from the population (Figure
1B).
It is through its function in surveil-
lance of genomic integrity and chromo-
somal structure that the p53 protein acts
as a second line of defense against the
initiating breaks. In the Zhu study, p53
function is removed via the knockout of
p53 genes, but in other tumors, a variety
of mechanisms exist to accomplish the
same purposes. These functions can be
permanently eliminated by a variety of
means that include (but are not confined
to) mutation of the gene, expression of
viral oncoproteins that bind and inacti-
vate the protein, or altered p53 metabo-
lism leading to increased proteolysis or
sequestration in an improper cellular
compartment. In addition to these more
standard inactivation mechanisms, p53
can be transiently inactivated by alter-
ations in epithelial cell adhesion (Nigro
et al., 1997) or Sirα2-mediated negative
control of p53 function during stress
(Luo et al., 2001). Without proper p53
function, cells with DNA lesions fail to
arrest cell cycle progression, fail to
senesce, and fail to activate apoptotic
pathways. Other collaborators of p53,
such as p63 and p73, are instrumental
in executing the apoptotic response
(Flores et al., 2002). These cells, defi-
cient in p53 function and gravid with the
products of improperly repaired interme-
diates, now have the ability to generate
a productive set of genomic rearrange-
ments that can provide selective advan-
tage and oncogenic potential to their
progeny (Figure 1C).
In the model system described by
Zhu et al., three specific events were nec-
essary to generate amplified DNA se-
quences with accompanying rearrange-
ments. These specific events identify
three general classes of alterations that
can contribute to the formation of these
structures in epithelial-derived tumors
that comprise the majority of malig-
nancies in humans. Other processes
endogenous or exogenous to the cell
(i.e., spontaneous hydrolysis of DNA or
radiation-induced breaks) can also gen-
erate DNA strand breaks similar to those
catalyzed by RAG. Deficiencies in
Ku70/80 function can be mimicked by
mutations in most of the other proteins
that contribute to the formation of the
complex protein machinery that repairs
DNA lesions and maintains genomic
integrity. Finally, abrogation of specific
p53 functions can occur through muta-
tion of the gene itself or alterations in its
critical downstream effectors. These
new insights into the events that gener-
ate amplified and rearranged DNA
sequences provide a mechanistic ap-
preciation of cancer initiation and pro-
gression independent of the RAG model
system.
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